• Skip to main content
  • Skip to footer
Eco Friendly CBD OIL

Eco Friendly CBD OIL

The Best Eco Friendly CBD Oil

  • Home
  • CBD Health
  • Cannabis News
  • Contact

CBD OIL

Shades Of Cannabis Reform & Confusion Across Europe Seem To Mirror US Progress

November 26, 2020 by CBD OIL

Cannabis reform is proceeding globally right now in some interesting places, and in an oddly syncopated schedule yet again.

Namely, in the last few weeks, change has been moving forward not only in the U.S., but Europe too. That this effort in the EU came literally weeks before the American presidential election where as of now, no matter who will occupy the White House, even more states move into the adult use camp is also surely no accident. Particularly given the results.

In South Dakota’s case, voters agreed to legalize both a medical and recreational market in a single election. In New Jersey, the referendum that passed authorized a market that is moving quickly to get implemented. This is equally intriguing. Namely that to the average person right now, no matter where they are, the continued delays and gridlock to get going, no matter the problems along the way, are increasingly unpopular politically. That too, is showing up at the ballot box.

Indeed, cannabis reform is now absolutely one of the most pressing and yet unaddressed issues in several countries at present. See New Zealand (where the voter mandate for adult use reform failed during their Presidential election last week).

Europe Seems To Be Following New Zealand’s Caution As Germany Delays Further Reform But…

Last week, a proposal on adult use cannabis reform failed in the German Bundestag (Parliament). With the exception of the far right Alternativ für Deutschland (AfD), every other political party agrees that there needs to be forward motion on the topic, but nobody seems to want to fully address it. This is no surprise. Indeed, the recent appointment of a former German minister last month to a Swiss cannabis company seems, certainly in retrospect, to presage the same. As well as the many protest votes on the topic emanating from Berlin, one way or the other.

However, in the aftermath of what is expected to be a widely influential medical case here (namely the regional approvers may not interfere with a doctor’s right to prescribe to qualified patients), it may be that the government wants more time to grow its medical program while Denmark, Holland and Luxembourg (if not Spain) figure out the logistics on the ground.

French flags blowing in the wind in Le Havre
French medical trials expected to begin Q2 of 2021

Given that France has finally committed to a national medical trial to begin no later than the second quarter of next year, and further one where it punts the majority of the cost onto the industry itself, this would create a solid “medical cannabis” bloc in Europe’s most affluent states. Not to mention the first real, nationally authorized patient trial in Europe that is not commercial.

But even this is not the whole story. While dickering about the certifications and scheduling of the plant go on now at the highest international levels, let alone federal ones domestically, hemp products are clearly entering the consumer market here – from upscale CBD stores in city centers to hemp seed oil and hemp-infused mayonnaise appearing on the shelves of German mainstream grocery stores. Not to mention hemp infused alcohol of at least the vodka, gin and rum varieties.

And then of course there is Italy.

The Italian Market May Be The Dark Horse In Europe Everyone Has Been Waiting For

Within literally the month of October, all in public view, the Italian government circled on the topic of legalizing the CBD/hemp market. As of last week, the Ministry of Health finally decided that cannabidiol sourced from hemp is not a narcotic.

CBD in Italy went from widely available to banned and back to available again.

Given the fact that home grow now is not illegal, and medical cannabis is technically available, it would seem that Italy is positioning its hemp market to survive if not thrive at least domestically and further thread the needle of industry continuity against fluid and further rapidly changing European and international regulation right now.

In the meantime, like Germany, however, the country is clearly angling to create an industry infrastructure – and further beyond the pharmaceutical vertical – via “other” channels before taking the final plunge. Cannabis Lite fits that bill perfectly.

What Does This Mean For 2021 And Beyond?

No matter the official denials, it is very clear that recreational cannabis reform at the American and Canadian ballot box is moving the conversation forward globally, even if at a different pace.

With the WHO now poised to weigh in on the issue, more American states signing up, an expanding medical market across the world and adult use upstarts everywhere, 2021 is absolutely sure to be a meaningful year just about everywhere on the cannabis front.

Filed Under: Cannabis News

Younger CBD consumers prefer CBD beverages over alcohol

November 26, 2020 by CBD OIL

Alcohol is on its way out among younger crowds, at least according to a new study. Younger consumers who are diverse and more affluent now prefer CBD beverages over alcohol for various reasons, including for socializing and “on-the-go” relief of anxiety, insomnia, and depression. The new information comes from cannabis market research firm High Yield Insights which ran a study this month of over 4,000 CBD users. The study included 1,200 people who drink CBD beverages.

According to the results, those consumers that use CBD drinks are younger, with 62 percent being Gen Z or Millennials. They are also affluent, with 33 percent living in households with income over $100,000.

The study also found that a significant number of respondents now use CBD since the beginning of the COVID-19 pandemic. The study also found that “CBD beverages users are much more likely than CBD users overall to use infused drinks to alleviate nausea and for exercise recovery. They also express more openness to household brands entering the CBD market.”

High Yield Insights collected the data in partnership with global consumer survey company InnovateMR. According to a statement released this week, it is the first study of its kind to research such consumer patterns concerning CBD and CBD beverages.

Furthermore, researchers note that the study also reviewed other categories, such as “currently used as well as those they would consider using or have discontinued using.”

According to a statement, “the study included over 35,000 respondents who answered key questions about their anxiety levels, impacts of the pandemic on their life, and their impressions of CBD products. Nearly 4,200 current CBD users gave additional responses about how and why they currently use CBD, product categories they would consider using in the future, and factors they consider when making a CBD purchase.”

“The beverage format appeals to consumers new to CBD because it is accessible, easy to dose, and resembles functional drinks in the mainstream market. Convenience was cited as a purchase driver for 42% of survey respondents and 45% report using other foods and beverages with enhanced ingredients,” said Mike Luce, President of High Yield Insights and a 20-year veteran in consumer insights and market research in a statement.

He continued: “CBD beverages is an omnichannel category as well. Drinks users are twice as likely to have purchased from a supermarket or drug store than CBD buyers overall. Picking up a single can or bottle is a relatively inexpensive solution for curious mainstream consumers. This is evident in the responses from non-users, who indicated greater interest in CBD beverages than any other format.”

Consumers use Hemp-derived CBD for many reasons. Research shows that many people use it for its anti-inflammatory and pain-relieving properties. Others prefer it because it has the potential to treat anxiety, stress, and depression. As a recent press release noted, “this has spurred increased interest in CBD as consumer seek out new products to add to their health and wellness repertoire. However, because many CBD companies are largely unknown by consumers, current and potential consumers face the challenge of finding a product suited to their needs.”

“The CBD market is ripe for innovation and brand-building,” noted Luce in a statement. “Of the 4,200 users surveyed, only 28 percent report having found a product, brand, or format that works for them. Efficacy is utmost in the mind of consumers. About 40 percent of CBD users indicated achieving the desired result as a driver for more frequent purchase, which was second only to lower prices.”

Original Article: https://www.potnetwork.com/news/younger-cbd-consumers-prefer-cbd-beverages-over-alcohol

Filed Under: CBD Health

NETA Announces Security Equipment Grant Program to Reduce Financial Barriers for Economic Empowerment and Social Equity Cannabis Businesses

November 26, 2020 by CBD OIL

FRANKLIN, Mass., Nov. 23, 2020 /PRNewswire/ — PRESS RELEASE — New England Treatment Access (NETA), a division of the privately-held, multi-state cannabis company Parallel and a cannabis operator in Massachusetts, has announced the launch of the first Security Equipment Grant Program designed to help reduce barriers to entry in the state’s cannabis industry for certified social equity and economic empowerment applicants.

The Security Equipment Grant Program will award $25,000 to two Economic Empowerment and/or Social Equity cannabis licensees to be used toward the purchase of compliant security equipment for their operations. Applicants must be provisionally licensed by the Cannabis Control Commission (CCC) to qualify.

The application can be found on the NETA website and will be accepted starting Nov. 23.

“We are excited to offer financial support to two certified social equity or economic empowerment cannabis operators through this new Security Equipment Grant Program. In introducing this program, our intent is to help lower the cost and complexity barriers that come with sourcing and installing security equipment for new cannabis operators,” said Kim Napoli, Sr. Director of Corporate Social Responsibility and Community Affairs for Parallel. “This grant program, in addition to other work we have done to support social equity and through our NETA Cares initiatives, is a sign of our commitment to fostering, cultivating and preserving a culture of diversity and inclusion in the cannabis industry in Massachusetts and all our markets.”

A team from NETA will review each application. The dollar amounts each awardee will receive will depend on the needs outlined in the application. The committee may decide to grant all monies or a portion of the requested funds each year, depending on the applicants’ requests. 

Filed Under: Cannabis News

CBD Topicals vs Oils: What’s The Difference?

November 26, 2020 by CBD OIL

Derived from the hemp plant, cannabidiol (CBD) can provide a host of benefits to the mind and body, all without inducing intoxicating effects.

But with all the different CBD products available on the market, how do you know which one to use? More specifically, CBD oil and topicals may be applied similarly. How do they compare to each other? How do they differ? And more importantly, which one should you use to target whatever ailment you’re experiencing?

CBD Oil

Oil can be applied topically to specific areas that are experiencing discomfort. It’s also an ideal substance to use for a massage, as oils help to lubricate the skin and minimize any friction while a massage is being performed.

The use of CBD oils during a massage also provides the opportunity to add essential oils to help both nourish the skin and provide an aromatic experience.

But CBD is also often taken orally, usually under the tongue using a dropper. By consuming CBD oil orally, it can have a more systemic effect on the entire body. [1]

CBD Topicals

Topicals can be further broken down into different formats, including tinctures, creams, salves, and ointments, each of which has a different texture, consistency, and base.

The different CBD topical formats may also differ in CBD potency, much like CBD oils. These types of products tend to be more commonly used to target specific areas of the body. [1]

Which Should You Use?

The decision between oils and topicals ultimately depends on the reason why you’re using CBD and what your comfort level and preference is. Generally speaking, both topicals and oils can work for pain management.

That said, topicals may be more effective for alleviating acute pain, inflammation, and headaches in a more targeted manner. They may also be more effective for treating skin issues, including eczema, psoriasis, and dermatitis. Further, topicals may be included in a regular skin care regimen to promote healthier skin.

But for those looking to manage chronic stress, anxiety, or insomnia, CBD oils that can be ingested orally may be optimal, as the effects will be more long lasting and impact the body as a whole. It is also easier to control dosing with the oral route. [1]

Having said all that, combining both topical CBD along with oral CBD may provide the best of both worlds. We always recommend speaking to your doctor before initiating CBD use. And it’s also important to test out different products to see which might work best for your body.

Image Credit: Silviarita

Image Source: https://pixabay.com/photos/oil-lip-balm-beeswax-flowers-4262839/

Reference

  1. Bruni N, et al. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. 2018;23(10):2478.

Filed Under: CBD Health

Shimadzu Announces Partnership with Missouri Lab

November 26, 2020 by CBD OIL

In a press release published last week, Shimadzu Scientific Instruments announced a partnership with MoCann Testing, a division of EKG Labs. MoCann Testing is the first state-certified medical cannabis testing lab in Missori.

It sounds like the partnership involves Shimadzu supplying MoCann with instruments and supporting their testing efforts with training, method development and maintenance, though the press release does not mention any details.

“We are excited to support MoCann’s mission to help individuals across the state of Missouri have access to safe medical marijuana through accurate sample testing and quality results,” says Bob Clifford, Ph.D., general manager of marketing at Shimadzu. “Because selecting the right analytical solutions is a critical investment, we provide more than just advanced instrumentation and software. We assist with method development, instrument training and maintenance that keep systems operating at the highest level.”

MoCann Testing is certified by Missouri, accredited to ISO 17025 and they offer the full gamut of testing services for growers and manufacturers in Missouri.

Filed Under: Cannabis News

Synthetic Cannabinoid For COVID-19 Approved For Phase I Trials

November 26, 2020 by CBD OIL

A synthetic cannabinoid drug known as ARDS-003 has been approved by the Food and Drug Administration (FDA) to start Phase 1 clinical trials. The substance is injectable and crafted to aid those with acute respiratory distress syndrome (ARDS), a serious condition prevalent with COVID-19.

ARDS is known to cause shortness of breath, rapid breathing, low blood pressure, and fatigue. Cytokines are proteins that cause inflammation. While inflammation is considered a healthy immune system response, too much of it can have fatal consequences (called cytokine release syndrome), especially in the setting of COVID-19 infection.

Cannabinoids have found a spotlight in treating ARDS, as research shows they can be natural anti-inflammatories–most notably, cannabidiol (CBD). [1]

The synthetic cannabinoid ARDS-003 was derived by researchers at Tetra Bio-Pharma. While this compound isn’t a natural molecule extracted from the cannabis plant, it’s engineered to act similarly to phytocannabinoids.

ARDS-003 interacts with the endocannabinoid system by binding to the cannabinoid receptor 2. This receptor plays an important role in regulating the immune system.

Guy Chamberland, MSc PhD, CEO and chief of regulatory officer at Tetra Bio-Pharma told Forbes, “We have extensive preclinical evidence that the active pharmaceutical ingredient in ARDS-003 has a profound effect in inhibiting the factors that lead to excessive immune system activation.”

While this isn’t going to prevent COVID-19 from spreading, it may just help those who are at risk from the novel coronavirus. Scientists have observed that those who struggle most with this virus have an inflamed respiratory system that can drown the lungs with excess fluid.

As ARDS-003 enters into Phase 1 of clinical trials, researchers will observe how it can help individuals with COVID-19. Whether or not the protective effects are long-lasting and are successful for people of all ages, ethnicities, and medical conditions remain to be seen.

Remember, there is no definitive evidence to date to show that using cannabinoids including CBD can prevent or treat COVID-19. Greater research is needed in this important area.

Reference

  1. Khodadadi H, et al. Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA. Cannabis Cannabinoid Res. 2020;5(3):197-201.

Image Credit: Michal Jarmoluk

Image Source: https://pixabay.com/photos/laboratory-analysis-chemistry-2815641/

Filed Under: CBD Health

4Front Ventures to Complete 185,000-Square-Foot Manufacturing Facility in Commerce, Calif.

November 26, 2020 by CBD OIL

<![CDATA[

PHOENIX November 24, 2020 – PRESS RELEASE – 4Front Ventures Corp. has announced that its fully funded, state-of-the-art, 185,000-square-foot production facility in Commerce, Calif., is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Leveraging its Washington facilities, 4Front has successfully introduced its products and brands into Massachusetts, Illinois and soon to be California. The automated, state-of-the-art Commerce facility incorporates unprecedented capacity for finished goods manufacturing, similar to the scale seen in the traditional consumer packaged goods industry. Commerce will have the ability to produce over 10 times the current capacity of 4Front’s 40,000-square-foot Washington production hub.

The successful closing of a C$17.25 million bought deal financing provides the company with all it needs to finish the California facility and to replicate its proven high-quality/low-cost production strategy that has been so successful in even the most competitive of cannabis markets such as Washington State.

“We’re thrilled to be in California and to be completing our largest and most automated manufacturing facility yet,” stated Leo Gontmakher, chief executive officer of 4Front. “Our experience in Washington, Massachusetts and Illinois, where we excel in low-cost manufacturing at scale, uniquely positions us to successfully compete in one of the largest, if not the largest, cannabis markets in the world.” 

Gontmakher continued, “This facility is almost finished and with our large-scale customized production line will produce a minimum of ten times more product per shift than the largest of our other locations. I am not aware of a production facility in the country which will rival us in either size or efficiency and we are poised to attack the California market in a manner that the rest of the industry has been unable to do.

“In short,” said Gontmakher, “this facility is expected to produce quality product at scale and at a price point that pleases both retailer and consumer. Being the lowest cost producer is our strategy for every state in which we operate, and I am excited to soon announce further capacity expansions in Illinois and Massachusetts as well."

]]>

Filed Under: Cannabis News

Study: Reddit Users Self-Medicate With CBD

November 26, 2020 by CBD OIL

What do consumers really think of cannabidiol (CBD)? Are they using it to treat medical conditions or wellness? To find out, researchers looked to the popular social media channel Reddit to see what the buzz is all about.

Scientists from the University of California San Diego performed a sweeping analysis of testimonials and the results were an emphatic confirmation of the momentum behind the promise of CBD.

The researchers scoured the r/CBD forum, digging up a staggering 104,917 posts (with 376 analyzed from a sample of 3,000 after filtering), spanning the period from January 2014 to August 2019. To organize all the information, they developed a coding system, which split testimonials into two categories. One revolved around CBD as a treatment of a diagnosable condition, which was made up of 11 subcategories, with the second category focused on wellness, which consisted of two subcategories.

The researchers found that 90% of the Reddit posters believed CBD can treat diagnosable conditions, including psychiatric disorders like depression, which were the most cited (63.9% of the posts), followed by orthopedic conditions (26.4% of the posts). Sleep disorders made up 14.6% of posts, and, finally, neurologic and gastroenterological issues at 6.9% and 3.9%, respectively. [1] Only 29.5%, in contrast, alluded to wellness benefits.

“Because CBD is not an FDA-approved treatment for nearly all the conditions cited by users who post to Reddit, CBD users may unnecessarily experience prolonged illnesses that would otherwise be alleviated with proven effective treatments,” the authors stated. “In addition, CBD use is not devoid of health risks.”

The study authors note some limitations, such as that results may not translate to the larger population, especially since Reddit users tend to be young and male. But the conclusions are telling:

“The findings of this case series suggest that the public may already perceive CBD as an effective therapeutic for many health conditions. We believe this misperception warrants a multipronged response encompassing regulation, clinical practice, and health education.”

While CBD has not undergone the vigorous clinical trial testing that approved treatments have followed, it is not fair to call these results a misperception, as there are many studies indicating that CBD and other cannabinoids can indeed be effectives across numerous medical conditions. This is evidenced by the approval of Epidiolex® (in the US) for epilepsy and Sativex® (outside the US) for symptoms of multiple sclerosis.

Certainly more data are needed and both physicians and consumers require far more education on CBD and cannabinoid medicine; but numbers don’t lie, and, if so many Reddit users find CBD effective, there must be something to it.

Image Credit: Gerd Altmann

Image Source: https://pixabay.com/photos/social-media-icon-human-personal-2537391/

Reference

  1. Leas EC, et al. Self-reported cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw Open. 2020;3(10):e2020977.

Filed Under: CBD Health

Spotlight on Aster Farms | Cannabis Industry Journal

November 26, 2020 by CBD OIL

The Brand Marketing Byte showcases highlights from Pioneer Intelligence’s Cannabis Brand Marketing Snapshots, featuring data-led case studies covering marketing and business development activities of U.S. licensed cannabis companies.

Here is a data-led, shallow dive on Aster Farms:

Aster Farms is based in Lake County, California and operates with an ethos of environmental sustainability. They call themselves the “cleanest, meanest and greenest around” and produce sungrown cannabis with “good genetics, clean cultivation and the power of nature.”

According to Pioneer Intelligence, Aster Farms is showing increased strength in each of the pillars they track: social media, earned media and web-related activities. The reason for such an improvement in performance? It starts with a number of earned media placements driving greater awareness for the brand, like this piece in SFWeekly or this one on Benzinga.

Engagement rates for Aster’s Instagram account have been growing for about two months and received a recent boost in the form of a sweepstakes giveaway. Their web activity performance improved as a result of keyword growth on their site.

All of these factors helped Aster Farms get on Pioneer’s list of Top 100 hottest U.S. cannabis brands for October, coming in at Number 60.

Filed Under: Cannabis News

Do Over-The-Counter CBD Products Have Enough CBD In Them?

November 26, 2020 by CBD OIL

Arguably the most popular cannabinoid on the planet right now is cannabidiol (CBD).

CBD’s popularity has grown exponentially in recent years.

In fact, CBD is searched for more often on Google compared to THC, and that has been the case for a handful of years now.

The rise in popularity for CBD has been paralleled by CBD’s availability in most countries.

People can purchase CBD products almost anywhere, from gas stations to online platforms.

In virtually every country that permits legal CBD sales, CBD is treated differently compared to THC from a regulation and public policy standpoint.

Whereas only two countries on earth allow sales of THC products for adult use, dozens of countries now allow CBD in one form or another.

Most CBD is derived from hemp as opposed to non-hemp cannabis, and as such it is easier to produce on a large scale compared to cannabis that is high in THC.

The abundance of global CBD supply is being infused into just about anything imaginable right now and many consumers are left wondering if the products they are purchasing are worth the money?

Not Enough CBD?

If you have ever searched for CBD products, then you are probably well aware that there are an incredible arrayt of options.

Figuring out which one is best for your particular situation can prove to be a daunting task.

A good place to start is to look at how much actual CBD is in the product.

According to a recent study conducted in the United Kingdom, the amount of CBD in a product varies widely.

The study was conducted by a team of investigators at King’s College in London and examined the safety and effectiveness of commercially marketed CBD products that are commonly available over-the-counter.

The researchers found that the contents of the CBD products involved in the study were of “variable quality” and that the amount of CBD in the products was significantly below the doses used in controlled clinical trials.

“Although there is enormous consumer interest in CBD, there is little evidence that OTC preparations have significant pharmacological activity or provide health benefits. … [C]ontrolled trials of OTC preparations are needed to address this issue. There is also a need for more accurate labelling and advertising of OTC CBD products,” the researchers concluded.

Dosage and Source Matter

As you can see from the results of the previously cited study, the amount of CBD in a product will make a considerable difference in how it effects users.

Microdosing may make sense when it comes to THC, however, the same does not appear true for CBD.

The quality of the hemp or non-hemp cannabis from which the CBD is sourced is obviously very important as well.

The proliferation of hemp cultivation around the globe in recent years has resulted in a lot of undesirable hemp-derived products flooding the market.

Make sure the CBD products you buy have sufficient CBD levels, that the CBD was sourced from quality hemp or non-hemp cannabis, and the labeling is accurate.

The easiest way to ensure that all happens is to only buy CBD from reputable companies.

Filed Under: CBD Health

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 111
  • Go to page 112
  • Go to page 113
  • Go to page 114
  • Go to page 115
  • Go to page 116
  • Go to Next Page »

Footer

  • Home
  • Privacy Policy
  • Terms of Service